Currenc Group, Inc. (CURR)
USD 1.56
(3.31%)
USD 1.56
(3.31%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 53.25 Million USD | 987.73% |
| 2022 | 4.89 Million USD | -25.31% |
| 2021 | 6.55 Million USD | 219.6% |
| 2020 | 2.05 Million USD | 229.21% |
| 2019 | 623 Thousand USD | 6.69% |
| 2018 | 583.94 Thousand USD | 223.69% |
| 2017 | 180.4 Thousand USD | 114.35% |
| 2016 | 84.16 Thousand USD | -54.12% |
| 2015 | 183.43 Thousand USD | -27.16% |
| 2014 | 251.83 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 287 Thousand USD | -97.81% |
| 2024 Q1 | 13.1 Million USD | 506.33% |
| 2023 Q2 | 972 Thousand USD | -21.49% |
| 2023 Q4 | -3.22 Million USD | -417.73% |
| 2023 FY | 53.25 Million USD | 987.73% |
| 2023 Q1 | 1.23 Million USD | 35.6% |
| 2023 Q3 | 1.01 Million USD | 4.42% |
| 2022 FY | 4.89 Million USD | -25.31% |
| 2022 Q1 | 1.1 Million USD | -31.75% |
| 2022 Q4 | 913 Thousand USD | -48.82% |
| 2022 Q3 | 1.78 Million USD | 58.86% |
| 2022 Q2 | 1.12 Million USD | 1.81% |
| 2021 FY | 6.55 Million USD | 219.6% |
| 2021 Q4 | 1.61 Million USD | 18.91% |
| 2021 Q1 | 1.44 Million USD | 10.31% |
| 2021 Q2 | 2.1 Million USD | 45.95% |
| 2021 Q3 | 1.35 Million USD | -35.56% |
| 2020 Q2 | 269 Thousand USD | -3.93% |
| 2020 FY | 2.05 Million USD | 229.21% |
| 2020 Q1 | 280 Thousand USD | -17.4% |
| 2020 Q4 | 1.31 Million USD | 582.29% |
| 2020 Q3 | 192 Thousand USD | -28.62% |
| 2019 Q3 | 102 Thousand USD | -5.49% |
| 2019 Q4 | 339 Thousand USD | 232.35% |
| 2019 FY | 623 Thousand USD | 6.69% |
| 2019 Q1 | 74.5 Thousand USD | -68.18% |
| 2019 Q2 | 107.92 Thousand USD | 44.87% |
| 2018 Q3 | 87.85 Thousand USD | -44.01% |
| 2018 Q2 | 156.91 Thousand USD | 49.43% |
| 2018 FY | 583.94 Thousand USD | 223.69% |
| 2018 Q4 | 234.15 Thousand USD | 166.54% |
| 2018 Q1 | 105.01 Thousand USD | 198.17% |
| 2017 Q3 | 74.35 Thousand USD | 91.22% |
| 2017 FY | 180.4 Thousand USD | 114.35% |
| 2017 Q1 | 31.94 Thousand USD | 0.0% |
| 2017 Q4 | 35.21 Thousand USD | -52.63% |
| 2017 Q2 | 38.88 Thousand USD | 21.72% |
| 2016 Q3 | - USD | -100.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | 2990.00 USD | 0.0% |
| 2016 Q2 | 7600.00 USD | 154.18% |
| 2016 FY | 84.16 Thousand USD | -54.12% |
| 2015 Q2 | 5905.00 USD | 0.0% |
| 2015 Q4 | - USD | -100.0% |
| 2015 Q3 | 2500.00 USD | -57.66% |
| 2015 FY | 183.43 Thousand USD | -27.16% |
| 2014 FY | 251.83 Thousand USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 88.532% |
| PainReform Ltd. | - USD | -Infinity% |
| Alvotech | 91.43 Million USD | 41.755% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 90.604% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 89.06% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -5.283% |
| Journey Medical Corporation | 79.18 Million USD | 32.742% |
| Dynavax Technologies Corporation | 232.28 Million USD | 77.073% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 54.222% |
| Bright Green Corporation | 401.49 Thousand USD | -13164.397% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 92.11% |
| Embecta Corp. | 1.12 Billion USD | 95.248% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -121.043% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -121.043% |
| SCYNEXIS, Inc. | 140.14 Million USD | 61.999% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -814.665% |
| Silver Spike Investment Corp. | 11.72 Million USD | -354.315% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -2661.496% |
| Alpha Teknova, Inc. | 36.68 Million USD | -45.173% |
| Safety Shot Inc | 202.67 Thousand USD | -26176.884% |
| Procaps Group, S.A. | 409.92 Million USD | 87.008% |
| Cosmos Health Inc. | 53.37 Million USD | 0.228% |
| Theratechnologies Inc. | 81.76 Million USD | 34.867% |
| Harrow Health, Inc. | 130.19 Million USD | 59.095% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -318.181% |
| Biofrontera Inc. | 34.07 Million USD | -56.307% |
| DURECT Corporation | 8.54 Million USD | -523.015% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 91.234% |
| Cronos Group Inc. | 88.84 Million USD | 40.055% |
| OptiNose, Inc. | 70.98 Million USD | 24.979% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 87.971% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -717.656% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 87.705% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -334.789% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -34.645% |
| Radius Health, Inc. | 2.88 Billion USD | 98.152% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -64.833% |
| ProPhase Labs, Inc. | 44.38 Million USD | -19.988% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 94.767% |
| Procaps Group S.A. | 409.92 Million USD | 87.008% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -3990.274% |
| Viatris Inc. | 15.42 Billion USD | 99.655% |
| Rockwell Medical, Inc. | 83.61 Million USD | 36.307% |
| Aytu BioPharma, Inc. | 81 Million USD | 34.254% |
| SIGA Technologies, Inc. | 139.91 Million USD | 61.938% |
| Tilray Brands, Inc. | 788.94 Million USD | 93.25% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 58.479% |
| Shineco, Inc. | 9.8 Million USD | -443.319% |
| PetIQ, Inc. | 1.1 Billion USD | 95.167% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -443694.675% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 97.178% |
| Alimera Sciences, Inc. | 80.75 Million USD | 34.052% |
| Assertio Holdings, Inc. | 152.06 Million USD | 64.979% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -205.767% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -4847.521% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -90.449% |
| Hempacco Co., Inc. | 4.04 Million USD | -1216.365% |
| Talphera, Inc. | 651 Thousand USD | -8080.547% |
| Alvotech | 91.43 Million USD | 41.755% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 83.18% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 95.892% |
| Kamada Ltd. | 144.75 Million USD | 63.211% |
| Indivior PLC | 1.09 Billion USD | 95.128% |
| Evoke Pharma, Inc. | 5.18 Million USD | -927.971% |
| Flora Growth Corp. | 76.07 Million USD | 29.993% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -4847.521% |
| Evolus, Inc. | 202.08 Million USD | 73.647% |
| HUTCHMED (China) Limited | 837.99 Million USD | 93.645% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 91.736% |
| Akanda Corp. | 2.16 Million USD | -2365.467% |